# Gilead Sciences, Inc. (GILD) — Q4-2016 Earnings Results

**Report date:** 2017-02-07 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q4-2016

## Post-Earnings Brief

### Headline

Gilead Sciences Beats on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.70 | N/A | +17.09% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation. They recognized market challenges but are focused on their product pipeline.

**Key quotes:**

> Management highlighted the strong performance in their key therapeutic areas.

> They acknowledged ongoing challenges in the market but expressed confidence in their pipeline.

> The focus remains on innovation and addressing unmet medical needs.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

Gilead Sciences reported a strong EPS performance, exceeding expectations by over 17%. However, the stock reaction is not available, indicating uncertainty in market response. The management's commentary suggests a focus on innovation despite market challenges, which could influence future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q4-2016_